VELARU MANDATE EXHIBIT PACK — GXP / FDA 21 CFR PART 11 PHARMA
Jurisdiction: New York (us_ny)
Modality: Text / Chat
Program: Velaru GxP / FDA 21 CFR Part 11 Pharma · New York (galactic_gxp_us_ny)
Product ID: gxp:us_ny:bundle:text
Vertical: gxp
Generated: 2026-08-22T17:54:09.932918Z
Authority: New York AI Governance Pack — GxP Electronic Records Integrity Pack
Deadline: NYDFS AI guidance + Local Law 144 enforcement
Velaru verify: https://velaru.xyz/verify

EXHIBIT A — AI INVENTORY
[
  {
    "named_entity": "Velari",
    "slug": "velari",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/4c58eac890bfd031ce2189de5a1ca9ea292a0c837f5f535daf164aef34f31e53",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/d8fb129c0c0c78d05256/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/velari"
  },
  {
    "named_entity": "LinkAudit Test",
    "slug": "linkaudit-test",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/58ddedd1974156453bc55daef6a9857d8570d56388becbb2a80bf5bac76b771b",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/78aa6e3f3a84cf1a88c0/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/linkaudit-test"
  },
  {
    "named_entity": "Link Audit Co",
    "slug": "link-audit-co",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/d00533b7b6c0495802b4250abd5c29f60bd9f2ad3fb141bba2d9a5afee5f5542",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/fea572f3996c4b963779/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/link-audit-co"
  }
]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 GxP / FDA 21 CFR Part 11 Pharma",
  "exhibit_authority": "New York AI Governance Pack \u2014 GxP Electronic Records Integrity Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "FDA 21 CFR Part 211 GMP",
    "ICH E6 GCP",
    "ICH Q10 Pharmaceutical Quality System",
    "EU GMP Annex 11",
    "WHO GMP guidelines",
    "FDA 483 observation risk",
    "NYDFS Circular Letter on AI",
    "NYC Local Law 144",
    "Martin Act"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release manufacturing batch",
  "third_party_verification": "https://velaru.xyz/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "QA releases batch on AI recommendation without hash-chained record \u2014 batch recall insurance void. \u00b7 Local Law 144 requires annual bias audit \u2014 Velaru receipts are continuous audit, not annual snapshot.",
  "chain_integrity": {
    "depth": 491,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "Delete audit trail before inspection = automatic consent decree pattern",
  "global_leaders_addressed": [
    "FDA",
    "Merck",
    "Lonza",
    "Waters Corporation",
    "ISPE",
    "NYDFS",
    "NYC DCWP",
    "Goldman Sachs"
  ]
}

MIRROR TRAP (regulatory insight)
QA releases batch on AI recommendation without hash-chained record — batch recall insurance void. · Local Law 144 requires annual bias audit — Velaru receipts are continuous audit, not annual snapshot.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "Deviation reports",
    "body": "AI flags GMP deviation \u2014 without receipt, QA cannot prove when they knew.",
    "source": "vertical"
  },
  {
    "title": "Annex 11 EU",
    "body": "European GMP requires same integrity \u2014 global pharma needs one primitive.",
    "source": "vertical"
  },
  {
    "title": "Recall insurance",
    "body": "Insurers deny recall claims when electronic records integrity violated.",
    "source": "vertical"
  },
  {
    "title": "[New York] Financial capital",
    "body": "NYDFS regulates insurers AND banks \u2014 same receipt primitive for both books.",
    "source": "jurisdiction"
  },
  {
    "title": "[New York] Hiring audit law",
    "body": "NYC AEDT law is template for other cities \u2014 receipt architecture scales municipally.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 3,
  "compliant": 0,
  "grace_period": 0,
  "non_compliant": 3,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: Every GMP facility globally · Part 11 is law today
INSURANCE LINES: Product recall, Pharma E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.